TY - JOUR
T1 - Identifying effective drug combinations for patients with acute myeloid leukemia
AU - Yilmaz, Musa
AU - Kadia, Tapan
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/7/2
Y1 - 2020/7/2
N2 - Introduction: The development of high-throughput sequencing technologies and the relentless pursuit of quality translational and clinical research allowed us to understand the leukemogenesis driven by recurrent mutations and design targeted therapies. As a result, the landscape of standard acute myeloid leukemia (AML) therapy has remarkably changed; only within the last few years, eight new agents were approved by the Food and Drug Administration for patients with AML. Areas covered: Although the addition of a new arsenal of AML drugs provides more options for patients, therapy decisions have become more challenging than it used to be. In the first section of this review, we summarized the clinical development of conventional combination regimens in AML, and in the second part, we focused on the development of novel and conventional chemotherapy combinations. Acute promyelocytic leukemia will not be discussed in this review. Expert opinion: The recurrent genomic aberrancies are not solely of prognostic relevance but can help with therapeutic decision-making at both diagnosis and relapse. Many challenges still remain to further improve on the survival of patients with AML, particularly for those with complex karyotype, secondary AML, or TP53 mutations. However, the pace of clinical drug development programs suggests a brighter future for our patients with AML.
AB - Introduction: The development of high-throughput sequencing technologies and the relentless pursuit of quality translational and clinical research allowed us to understand the leukemogenesis driven by recurrent mutations and design targeted therapies. As a result, the landscape of standard acute myeloid leukemia (AML) therapy has remarkably changed; only within the last few years, eight new agents were approved by the Food and Drug Administration for patients with AML. Areas covered: Although the addition of a new arsenal of AML drugs provides more options for patients, therapy decisions have become more challenging than it used to be. In the first section of this review, we summarized the clinical development of conventional combination regimens in AML, and in the second part, we focused on the development of novel and conventional chemotherapy combinations. Acute promyelocytic leukemia will not be discussed in this review. Expert opinion: The recurrent genomic aberrancies are not solely of prognostic relevance but can help with therapeutic decision-making at both diagnosis and relapse. Many challenges still remain to further improve on the survival of patients with AML, particularly for those with complex karyotype, secondary AML, or TP53 mutations. However, the pace of clinical drug development programs suggests a brighter future for our patients with AML.
KW - AML
KW - Combination chemotherapy
KW - novel drug
KW - triplet therapy
UR - http://www.scopus.com/inward/record.url?scp=85087477006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087477006&partnerID=8YFLogxK
U2 - 10.1080/14737140.2020.1782749
DO - 10.1080/14737140.2020.1782749
M3 - Review article
C2 - 32552126
AN - SCOPUS:85087477006
SN - 1473-7140
VL - 20
SP - 591
EP - 601
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 7
ER -